12 citations
,
December 2012 in “Current Drug Targets”
The AndrogenReceptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.
The post discusses using 2% ketoconazole shampoo as a competitiveandrogenreceptorantagonist for hair loss, applied for 1.5 hours daily. The user questions its effectiveness and potential benefits compared to finasteride and minoxidil.
The conversation discusses topical androgenreceptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgenreceptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, and Nizoral shampoo. Nizoral's effectiveness is debated, with some suggesting it works as a weak antagonist for androgenreceptors, while others attribute its benefits to anti-fungal and anti-inflammatory properties.
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgenreceptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.